TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22567069
Drug: Biofeedback-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-based stress management tool used three times daily
Study: 10630736
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg daily for 12 weeks
Study: 10630736
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg daily for 12 weeks
Study: 6391236
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 g of glucose added to porcine insulin (0.4 Ul.g-1)
Study: 6391236
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion without insulin
Study: 29351748
Drug: Medication (acetaminophen)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (acetaminophen)
Study: 24557758
Drug: Mydriasert (ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mydriasert (ophthalmic insert containing tropicamide and phenylephrine)
Study: 22089379
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice/day)
Study: 9495425
Drug: Granisetron 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2.5 mg (Group G)
Study: 2258249
Drug: SR nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR nicardipine (40 mg b.i.d.)
Study: 2684073
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg once daily)
Study: 27830643
Drug: Simulator-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulator-based occupational therapy driving intervention (OT-DI); 3 sessions addressing driving errors and visual-search retraining
Study: 24809482
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S (shallow block) with rocuronium 0.45 mg kg-1
Study: 24809482
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (deep block) with rocuronium 0.6 mg kg-1
Study: 20379032
Drug: Cold polymerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold polymerized soft liner (Visco Gel)
Study: 17524123
Drug: New 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 4% hydroquinone cream
Study: 17524123
Drug: Commercial 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial 4% hydroquinone creams
Study: 16253600
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/day (n = 48)
Study: 16253600
Drug: no lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: no lipid-lowering treatment (n = 43)
Study: 11876795
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of IFN-alpha thrice weekly for 24 weeks
Study: 1690551
Drug: Oral ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral ribavirin 600 mg
Study: 1690551
Drug: Oral ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral ribavirin 800 mg
Study: 42523
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine and 50 mg methanthelinebromide
Study: 42523
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg methanthelinebromide
Study: 31416768
Drug: MTBVAC (5×10^5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTBVAC (5×10^5 CFU in 0.1 mL)
Study: 31416768
Drug: BCG Vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG Vaccine SSI (5×10^5 CFU in 0.1 mL)
Study: 31416768
Drug: MTBVAC (2.5×10^3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTBVAC (2.5×10^3 CFU in 0.05 mL)
Study: 31416768
Drug: MTBVAC (2.5×10^4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTBVAC (2.5×10^4 CFU in 0.05 mL)
Study: 31416768
Drug: MTBVAC (2.5×10^5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTBVAC (2.5×10^5 CFU in 0.05 mL)
Study: 31416768
Drug: BCG Vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG Vaccine SSI (2.5×10^5 CFU in 0.05 mL)
Study: 25771480
Drug: Other hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hand therapy treatments (control)
Study: 22561230
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg once daily for 24 weeks
Study: 22561230
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily for 24 weeks
Study: 16499476
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg, orally, three times a day for 2 days)
Study: 12521832
Drug: 17‐beta oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐beta oestradiol 25‐mg vaginal tablets
Study: 9773136
Drug: Very slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very slow injection of local anaesthetic (injection time 100 to 150 seconds, Group A)
Study: 9773136
Drug: Faster injection
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster injection of local anaesthetic (injection time 40 to 80 seconds, Group B)
Study: 600190
Drug: Timolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (5 mg to 20 mg) with hydrochlorothiazide
Study: 600190
Drug: Moduretic (hydrochlorothiazide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moduretic (hydrochlorothiazide, 50 mg and amiloride, 5 mg) with timolol
Study: 29083391
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (traction, strengthening, stretching exercises)
Study: 23284039
Drug: Complete resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete resection before chemotherapy
Study: 23284039
Drug: Incomplete resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete resection before chemotherapy
Study: 23284039
Drug: Biopsy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy or no surgery before chemotherapy
Study: 23284039
Drug: Complete resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete resection after induction chemotherapy
Study: 23284039
Drug: Incomplete resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete resection after induction chemotherapy
Study: 23284039
Drug: Biopsy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy or no surgery after induction chemotherapy
Study: 18851852
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g of elemental calcium)
Study: 16281880
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isotretinoin + 0.05% tretinoin cream
Study: 16281880
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isotretinoin + 0.05% tretinoin cream
Study: 16281880
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg isotretinoin/kg bodyweight + 0.05% tretinoin cream + oral methylprednisolone
Study: 16281880
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg isotretinoin/kg bodyweight + 0.05% tretinoin cream
Study: 11724639
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg acute, titrated to 16 mg daily chronic)
Study: 31482417
Drug: Gentamicin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2.5 mg/kg every 12 hours (Group 1)
Study: 31482417
Drug: Gentamicin 4
Normalized name: gentamicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4 mg/kg every 36 hours (Group 2)
Study: 31482417
Drug: No Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Gentamicin therapy (Group 3)
Study: 28279833
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg sc weekly for 26 weeks
Study: 16225841
Drug: Task Concentration
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Task Concentration Training (TCT) combined with Cognitive Therapy (CT)
Study: 27504532
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied to one side of the jaw
Study: 22666779
Drug: 4% succinylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% succinylated gelatin (gelofusine solution) (group JEL)
Study: 15709546
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral immunonutrition for 5 days
Study: 15709546
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (no supplementation)
Study: 12408922
Drug: Formulation R
Normalized name: Formulation R
DrugBank: Hydrogenated palm kernel oil (DB11144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation R (400 mg)
Study: 12408922
Drug: Formulation T
Normalized name: ABANEU-SL Cobalamin Complex Formulation Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation T (400 mg)
Study: 7497762
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms/d)
Study: 6120713
Drug: Astemizole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (20 mg)
Study: 23574730
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg/day)
Study: 19204211
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids vs placebo
Study: 19204211
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long-acting β-agonists vs long-acting β-agonists
Study: 14769141
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange plus conventional cancer chemotherapy
Study: 14769141
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange plus continuous oral cyclophosphamide
Study: 11677866
Drug: Bisoprolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol therapy
Study: 7527328
Drug: Lacidipine 2
Normalized name: lacidipine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 2 to 8 mg/day for 1 to 4 months
Study: 7527328
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 to 6 mg once daily
Study: 23070789
Drug: Flavonoid-rich juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich juice (JUICE) 16 fl oz (230 mg flavonoids) ingested pre- and postworkout for 10 days
Study: 30194618
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion sonohysterography (SIS)
Study: 18405345
Drug: Dispensing medication
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispensing medication packaged in the electronic medication-monitoring device
Study: 18405345
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication packaging
Study: 9097297
Drug: d,l-fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-fenfluramine (60 mg p.o.)
Study: 3080695
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous TRH (500 mg)
Study: 3080695
Drug: Chronic subcutaneous
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic subcutaneous TRH (25 mg daily for 3 months)
Study: 27741339
Drug: 4% 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% 5-Fluorouracil cream once daily for 4 weeks
Study: 27741339
Drug: 5% 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-Fluorouracil cream twice daily for 4 weeks
Study: 27741339
Drug: 4% 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% 5-Fluorouracil cream once daily for 2 weeks
Study: 19897255
Drug: Home-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based daily muscle training for 12 months
Study: 15723739
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil omega-3 fatty acids (3 g/d)
Study: 15723739
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil omega-3 fatty acids (3 g/d) and olive oil (9.6 mL)
Study: 12793996
Drug: 1-g aspirin
Normalized name: aspirin 1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g aspirin treatment
Study: 12545825
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + PA-MSHA vaccine
Study: 8806338
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and No drug therapy (Control)
Study: 29722146
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole 4 hours before EST and then every 12 hours for 1 day, followed by high-dose oral esomeprazole for 10 days
Study: 22681960
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole
Study: 26540314
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) with panitumumab (6 mg/kg) for up to 12 cycles (arm A)
Study: 26540314
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) without panitumumab (arm B)
Study: 20386070
Drug: bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily)
Study: 20386070
Drug: lopinavir/ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (400/100 mg twice daily)
Study: 10206447
Drug: Metformin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5 to 2.25 g/d) for 6.1+/‐5.1 months
Study: 10206447
Drug: Metformin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5 to 2.25 g/d)
Study: 8580383
Drug: RFLP‐A polymorphism
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFLP‐A polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Study: 8580383
Drug: RFLP‐B polymorphism
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFLP‐B polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Study: 613552
Drug: Parenteral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral treatment with triamcinolone acetonide (Kenacort A) - 80 mg for the 1st and 2nd injections, 40 mg for the 3rd to 7th injections at two-week intervals
Study: 613552
Drug: Parenteral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral treatment with triamcinolone acetonide (Kenacort A)
Study: 613552
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with prednisolone - initial dosage of 30 mg followed by reduced dosage for 6 months
Study: 28822974
Drug: Dexmedetomidine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (3.5 μg/kg + 5 μg/kg/hour CRI)
Study: 28822974
Drug: Dexmedetomidine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (3.5 μg/kg + 3.5 μg/kg/hour CRI) and Butorphanol (20 μg/kg + 24 μg/kg/hour CRI)
Study: 24791752
Drug: Oral GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GSH 1,000 mg/day
Study: 24791752
Drug: Oral GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GSH 250 mg/day
Study: 23499546
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil (16 weeks, twice a week)
Study: 23499546
Drug: Electrocautery (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocautery (monthly for 4 months)
Study: 23499546
Drug: Topical fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluorouracil
Study: 18034397
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination therapy of dexamethasone and gentamicin
Study: 17974421
Drug: 1‐alpha(OH) vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐alpha(OH) vitamin D3 (0.25 mcg twice a day)
Study: 17974421
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with calcium (500 mg daily)
Study: 27082747
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for substance use (specifics not provided)
Study: 25087414
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser blood irradiation for 10 days, using a laser therapeutic device Matrix - VLOK with two radiating heads (KI-VLOK-63 and KI-VLOK-365).
Study: 10084637
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day risperidone
Study: 10084637
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day risperidone
Study: 10084637
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day risperidone
Study: 7474246
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.5%) eye drops
Study: 7474246
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol (0.5%) eye drops with oral quinidine (50 mg)
Study: 2270452
Drug: Paracetamol (i.v.)
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (i.v.)
Study: 25845393
Drug: Daily reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reminders via alarm and follow-up calls from peer-educators
Study: 19058060
Drug: Balance-strategy training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance-strategy training program (twice-weekly for 12 weeks)
Study: 15289275
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion (TD) induced by administering capsules containing an amino acid mixture without tryptophan.
Study: 15289275
Drug: Sham depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham depletion using identical capsules containing hydrous lactose.
Study: 22784432
Drug: Optimized rapeseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized rapeseed oil (20 g/d)
Study: 22784432
Drug: Standard rapeseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rapeseed oil (20 g/d)
Study: 16497603
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) using a nicotine skin patch for 2 weeks before the quit date, with doses of 0, 21, or 42 mg/24-hr after the quit date in combination with mecamylamine (10 mg/day).
Study: 16497603
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patch treatment
Study: 16497603
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patches with reduced-nicotine cigarettes
Study: 11704711
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (exact dosage and duration not specified)
Study: 9397385
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal norethisterone acetate (NETA) 170 micrograms
Study: 9397385
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal norethisterone acetate (NETA) 350 micrograms
Study: 9397385
Drug: Sequential oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential oral progestogen (1 mg norethisterone or 20 mg dydrogesterone/day)
Study: 9397385
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal progestogen
Study: 9397385
Drug: Continuous progestogen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous progestogen (low-dose)
Study: 9397385
Drug: Continuous progestogen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous progestogen (high-dose)
Study: 9397385
Drug: Oral progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral progestogen group
Study: 20606148
Drug: Glucosamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (1500 mg daily for 6 months)
Study: 31910279
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 6 months)
Study: 12887260
Drug: Interferon (IFN)‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐beta treatment
Study: 9773135
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg
Study: 26332408
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with fixed appliances
Study: 25945760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without orthodontic treatment)
Study: 7978092
Drug: Ethanol 0.5
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.5 g/kg
Study: 11590628
Drug: Rank-based methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rank-based methods for analysis of outcomes with rescue medication
Study: 11590628
Drug: Multilevel regression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel regression model relating outcome to allocated treatment and rescue status
Study: 8022438
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (20 mg intravaginally every 3 hours)